Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Etoposide 6Radiotherapy 4Cisplatin 3Docetaxel 2Carboplatin 2venetoclax 1trametinib 1toripalimab 1tislelizumab 1talazoparib 1sacituzumab govitecan 1rovalpituzumab tesirine 1regorafenib 1poly ICLC 1pembrolizumab 1olaparib 1obatoclax 1nintedanib 1fludarabine phosphate 1etoposide phosphate 1enoxaparin sodium 1durvalumab 1alpha-Tocopherol 1Vitamin E 1Topotecan 1Tomography, Optical Coherence 1Thymalfasin 1Taxes 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Small Cell Lung Carcinoma × enoxaparin sodium × Clear all
NCT00916669 2013-05-08

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Massachusetts General Hospital

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡